

Information Disclosure Statement

In accordance with their duty of disclosure under 37 C.F.R. § 1.56, applicants would like to direct the Examiner's attention to the following reference which is listed on the attached Form PTO-1449 (**Exhibit A**) and a copy of which is attached hereto as **Exhibit 1**:

1. U.S. Serial No. 09/764,710, filed January 17, 2001, Michael Konkell, et al. (**Exhibit 1**).

In accordance with their duty of disclosure under 37 C.F.R. § 1.56, applicants would like to direct the Examiner's attention to the following disclosures which are listed on the attached Form PTO-1449 (**Exhibit A**) and which were previously submitted or cited in connection with the prosecution of U.S. Serial No. 09/764,710 from which the subject application claims priority under 35 U.S.C. § 120. According to 37 C.F.R. § 1.98(d), copies of patents or publications that were previously cited by, or submitted to, the Patent Office in connection with such prior applications need not accompany the Information Disclosure Statement. Accordingly, copies of the following references are not attached to this Information Disclosure Statement.

1. PCT International Application No. WO 01/05765, published January 25, 2001;
2. PCT International Publication No. WO 99/57131, published November 11, 1999;
3. Snowball, R.K. et al. Investigation of the role of α_{1A} - and α_{1D} - adrenoceptors in the control of the "micturition reflex" in the anaesthetized male rat. British Journal of Pharmacology, Proceedings of the British Pharmacology

Michael Konkel, et al.
Serial No.: 09/764,710
Filed: January 17, 2001
Page: 7

Society Meeting January 5-7, 2000, Abstract 35P;

4. U.S. Patent No. 3,398,151, issued August 20, 1968, Wu;
5. U.S. Patent No. 3,558,777, issued January 26, 1971, Wu;
6. U.S. Patent No. 4,988,700, issued January 29, 1991, Traber et al.;
7. U.S. Patent No. 5,070,102, issued December 3, 1991, Traber et al.;
8. U.S. Patent No. 5,096,908, issued March 17, 1992, Gidda and Schaus;
9. U.S. Patent No. 5,155,128, issued October 13, 1992, Traber et al.;
10. U.S. Patent No. 5,200,410, issued April 6, 1993, Traber et al.;
11. U.S. Patent No. 5,258,379, issued November 2, 1993, Gidda and Schaus;
12. U.S. Patent No. 5,294,619, issued March 15, 1994, Nagel;
13. European Patent Application No. 0 372 776, published June 13, 1990, Nagel;
14. European Patent Application No. 0 395 312, published October 31, 1990, Cliffe;
15. European Patent Application No. 0 447 345, published September 18, 1991, Orjales-Venero and Rodes-Solanes;


16. European Patent Office No. 0 455 510, published November 6, 1991, Gidda and Schaus;
17. German Patent DE 40 39 631, published June 17, 1992;
18. Goetz, A.S. et al., BMY 7378 is a selective antagonist of the D subtype of α_1 -adrenoceptors. Eur. J. Pharmacol. (1995) 272: R5-R6;
19. Lopez-Rodriguez et al., 1-[(4-Arylpiperazin-1-yl)alkyl]-3-diphenylmethylen-2,5-pyrrolidinediones as 5-HT_{1A} receptor ligands: study of the steric requirements of the terminal amide fragment on 5-HT_{1A} affinity/selectivity. Bioorganic & Medicinal Chemistry Letters (1998) 8: 581-586;
20. Saussy, D.L. Jr. et al., Structure activity relationships of a series of buspirone analogs at alpha-1 adrenoceptors: Further evidence that rat aorta alpha-1 adrenoceptors are of the alpha-1D-subtype. J. Pharmacol. Exp. Ther. (1996) 278: 136-144; and
21. Wu, Y.-H. et al., Psychosedative agents. N-(4-Phenyl-1-piperazinylalkyl)-substituted cyclic imides. J. Med. Chem. (1969) 12: 876-881.

Michael Konkel, et al.
Serial No.: 09/764,710
Filed: January 17, 2001
Page: 9

If a telephone interview would be of assistance in advancing prosecution of the above-identified application, Applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee, other than the enclosed fee of \$1,060.00 for filing the subject application is deemed necessary in connection with the filing of this Preliminary Amendment and Information Disclosure Statement. However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 1795/54927-AA-PCT- US/JPW/ANX		Serial No. Not Yet Known								
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Applicants Michael Konkel, et al.		Group Art Unit Not Yet Known								
				Filing Date Herewith										
U.S. PATENT DOCUMENTS														
Examiner Initial		Document Number						Date	Name	Class	Subclass	Filing Date if Appropriate		
	US	3	3	9	8	1	5	1	08/20/68	Wu				
	US	3	5	5	8	7	7	7	01/26/71	Wu				
	US	4	9	8	8	7	0	0	01/29/01	Traber, et al.				
	US	5	0	7	0	1	0	2	12/3/91	Traber, et al.				
FOREIGN PATENT DOCUMENTS														
		Document Number						Date	Country	Class	Subclass	Translation		
		9	9	5	7	1	3	1	November 11, 1999	PCT			Yes	No
		0	3	7	2	7	7	6	June 13, 1990	EPO				
		0	3	9	5	3	1	2	October 31, 1990	EPO				
		0	4	4	7	3	4	5	September 18, 1991	EPO				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)														
		Snowball, R.K. et al. Investigation of the role of α_{1A} - and α_{1D} - adrenoceptors in the control of the "micturition reflex" in the anaesthetized male rat. British Journal of Pharmacology, Proceedings of the British Pharmacology Society Meeting January 5-7, 2000, Abstract 35P;												
		Goetz, A.S. et al., BMJ 7378 is a selective antagonist of the D subtype of α_1 -adrenoceptors. Eur. J. Pharmacol. (1995) 272: R5-R6;												
		Lopez-Rodriguez et al., 1-[ω (4-Arylpiperazin-1-yl)alkyl]-3-diphenylmethylene-2,5-pyrrolidinediones as 5-HT _{1A} receptor ligands: study of the steric requirements of the terminal amide fragment on 5-HT _{1A} affinity/selectivity. Bioorganic & Medicinal Chemistry Letters (1998) 8: 581-586;												
EXAMINER								DATE CONSIDERED						
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 1795/54927-AA-PCT- US/JPW/ANX		Serial No. Not Yet Known								
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Applicants Michael Konkel, et al.										
				Filing Date Herewith		Group Art Unit Not Yet Known								
U.S. PATENT DOCUMENTS														
Examiner Initial	US	Document Number				Date	Name	Class	Subclass	Filing Date if Appropriate				
	US	5	0	9	6	9	0	8	3/17/92	Gidda and Schaus				
	US	5	1	5	5	1	2	8	10/13/92	Traber, et al.				
	US	5	2	0	0	4	1	0	4/6/93	Traber, et al.				
	US	5	2	5	8	3	7	9	11/2/93	Gidda and Schaus				
	US	5	2	9	4	6	1	9	3/15/94	Nagel				
FOREIGN PATENT DOCUMENTS														
		Document Number				Date	Country	Class	Subclass	Translation				
		0	4	5	5	5	1	0	Nov. 6, 1991	EPO			Yes	No
		4	0	3	9	6	3	1	June 17, 1992	Germany				
		0	1	5	6	7	6	5	January 25, 2001	PCT				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)														
		Saussy, D.L. Jr. et al., Structure activity relationships of a series of buspirone analogs at alpha-1 adrenoceptors: Further evidence that rat aorta alpha-1 adrenoceptors are of the alpha-1D-subtype. J. Pharmacol. Exp. Ther. (1996) 278: 136-144;												
		Wu, Y.-H. et al., Psychosedative agents. N-(4-Phenyl-1-piperazinylalkyl)-substituted cyclic imides. J. Med. Chem. (1969) 12: 876-881;												
		U.S. Serial No. 09/764,710, filed January 17, 2001, Michael Konkel, et al. (Exhibit 1)												
EXAMINER								DATE CONSIDERED						
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														